• Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE
• 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2
• All secondary efficacy endpoints met with statistical significance
• Well-tolerated safety profile of deucrictibant XR demonstrated
• Conference call and webcast today at 8:00 a.m. EDT

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.